Skip to main content

Table 3 Treatment related toxicities

From: A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

 

Arm A (N = 14)

Grade

1,2

3

4

5

 

(n)

(n)

(n)

(n)

Allergic reaction

1

-

-

-

Hemoglobin

5

-

-

-

Leukocytes

-

1

-

-

Neutrophils

1

1

-

-

Platelets

3

1

1

-

Hypertension

6

1

-

-

Fatigue

7

4

1

-

Weight loss

1

-

-

-

Flushing

1

-

-

-

Alopecia

1

-

-

-

Pruritus/itching

1

-

-

-

Rash/desquamation

5

3

-

-

Hand-foot reaction

3

1

-

-

Skin-other

1

-

-

-

Anorexia

3

-

-

-

Constipation

2

-

-

-

Dehydration

-

1

-

-

Diarrhea w/o prior colostomy

6

2

-

-

Flatulence

1

-

-

-

Dyspepsia

3

-

-

-

Muco/stomatitis (symptom) oral cavity

2

-

-

-

Nausea

1

1

-

-

GI-other

1

-

-

-

Infection Gr0-2 neut, urinary tract

1

-

-

-

Infection w/ unk ANC upper airway NOS

1

-

-

-

ALT, SGPT

4

-

-

-

AST, SGOT

5

-

-

-

Bilirubin

3

-

-

-

Hyponatremia

-

1

-

-

Nonneuropathic generalized weakness

-

1

-

-

Musculoskeletal/soft tissue-other

1

-

-

-

Dizziness

1

1

-

-

Neuropathy-sensory

2

-

-

-

Extremity-limb, pain

1

-

-

-

Head/headache

1

-

-

-

Joint, pain

1

1

-

-

Muscle, pain

2

-

-

-

Dyspnea

1

-

-

-

Worst degree

5

7

2

-